[go: up one dir, main page]

DK1149078T3 - Selektive 5-HT6-receptorligander - Google Patents

Selektive 5-HT6-receptorligander

Info

Publication number
DK1149078T3
DK1149078T3 DK99967248T DK99967248T DK1149078T3 DK 1149078 T3 DK1149078 T3 DK 1149078T3 DK 99967248 T DK99967248 T DK 99967248T DK 99967248 T DK99967248 T DK 99967248T DK 1149078 T3 DK1149078 T3 DK 1149078T3
Authority
DK
Denmark
Prior art keywords
selective
receptor ligands
receptors
compounds
treatment
Prior art date
Application number
DK99967248T
Other languages
Danish (da)
English (en)
Inventor
Bryan L Roth
Richard A Glennon
Original Assignee
Univ Virginia Commonwealth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Virginia Commonwealth filed Critical Univ Virginia Commonwealth
Application granted granted Critical
Publication of DK1149078T3 publication Critical patent/DK1149078T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/86—Carbazoles; Hydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Escalators And Moving Walkways (AREA)
  • Electric Double-Layer Capacitors Or The Like (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Conductive Materials (AREA)
  • Control Of High-Frequency Heating Circuits (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DK99967248T 1998-12-11 1999-12-10 Selektive 5-HT6-receptorligander DK1149078T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11178798P 1998-12-11 1998-12-11

Publications (1)

Publication Number Publication Date
DK1149078T3 true DK1149078T3 (da) 2006-07-10

Family

ID=22340454

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99967248T DK1149078T3 (da) 1998-12-11 1999-12-10 Selektive 5-HT6-receptorligander

Country Status (10)

Country Link
EP (1) EP1149078B1 (fr)
AT (1) ATE319683T1 (fr)
AU (1) AU767009B2 (fr)
CA (1) CA2353962C (fr)
DE (1) DE69930308T2 (fr)
DK (1) DK1149078T3 (fr)
ES (1) ES2260958T3 (fr)
MX (1) MXPA01005905A (fr)
PT (1) PT1149078E (fr)
WO (1) WO2000034242A1 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002032863A1 (fr) 2000-10-20 2002-04-25 Biovitrum Ab N1-(benzensulfonyl)indoles substitues en 2, 3, 4 ou 5 et leur utilisation a des fins de traitement
CZ305838B6 (cs) * 2001-03-29 2016-04-06 Eli Lilly And Company N-(2-arylethyl)benzylaminy jako antagonisté receptoru 5-HT6
EP1859798B1 (fr) * 2001-03-29 2015-12-30 Eli Lilly And Company N-(2-aryléthyl)benzylamines antagonistes du récepteur 5-ht6
CA2445653A1 (fr) 2001-06-11 2002-12-19 Biovitrum Ab Composants de sulfonamide substitues, procede d'utilisation de ceux-ci comme medicaments dans le traitement de troubles cns, de l'obesite et du diabete de type ii
ITRM20010356A1 (it) * 2001-06-21 2002-12-23 Sigma Tau Ind Farmaceuti "5-alogeno derivati della triptamina utili come ligandi del recettore5-ht6 e/o 5-ht7 della serotonina.
EP1897876A3 (fr) 2002-06-20 2009-03-18 Biovitrum AB (publ) Composés utiles pour le traitement de l'obésité, du diabète de type II et des troubles du système nerveux central
RU2340619C2 (ru) * 2002-06-21 2008-12-10 Сувен Лайф Сайенсиз Лимитед Новые тетрациклические арилсульфонилиндолы с аффинностью к серотониновым рецепторам, пригодные в качестве лекарственных средств, способ их получения и содержащие их фармацевтические композиции
KR100739987B1 (ko) 2002-12-18 2007-07-16 수벤 라이프 사이언시스 리미티드 세로토닌 수용체 친화력을 가지는 테트라사이클릭 3-치환인돌
MXPA05013652A (es) 2003-06-26 2006-02-24 Takeda Pharmaceutical Modulador del receptor canabinoide.
DE602004008474T2 (de) * 2003-07-31 2008-05-15 Wyeth N-sulfonylheterocyclopyrrolylalkylamin-verbindungen als 5-hydroxytryptamin-6-liganden.
SE0303480D0 (sv) 2003-12-19 2003-12-19 Biovitrum Ab Benzofuranes
JP2008518917A (ja) 2004-11-01 2008-06-05 ワイス Ｃｎｓ薬剤としての置換インドリジンおよび誘導体
US7582767B2 (en) 2005-06-17 2009-09-01 Biovitrum Ab (Publ.) Substituted sulphonamide compound and uses thereof
ES2354455T3 (es) * 2005-10-19 2011-03-15 Suven Life Sciences Limited Derivados de carbazol como ligandos funcionales de 5-ht6.
BRPI0808791A2 (pt) 2007-03-13 2017-05-02 Biovitrum Ab (Publ) derivados tricíclicos de isoquinolina para tratamento de obesidade
CA2706651A1 (fr) 2007-12-04 2009-06-11 Merck Sharp & Dohme Corp. Tryptamine sulfonamides en tant qu'antagonistes de 5-ht6
EP2103596A1 (fr) 2008-03-18 2009-09-23 Laboratorios Del. Dr. Esteve, S.A. Procédé pour la préparation de sels d'analine de N-(phényléthyle) et leurs solvates utiles en tant qu'antagonistes de la sérotonine 5-HT6
GB0905328D0 (en) * 2009-03-27 2009-05-13 Ge Healthcare Ltd Indole derivatives
FR2961097B1 (fr) * 2010-06-09 2012-07-13 Oreal Procede cosmetique de traitement des odeurs corporelles humaines utilisant un compose 6-alkoxy tryptamine
FR2961095B1 (fr) * 2010-06-09 2012-06-15 Oreal Composition cosmetique et/ou dermatologique comprenant au moins un compose 6-alcoxy tryptamine
US9073851B2 (en) 2011-10-28 2015-07-07 Board Of Regents, The University Of Texas System Compositions and methods for treating cancer
JO3459B1 (ar) 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر
CN115667217A (zh) 2020-05-19 2023-01-31 赛本爱尔兰有限公司 氘化的色胺衍生物和使用方法
AU2021397252B2 (en) * 2020-12-09 2024-03-14 Caamtech, Inc. Dialkyl tryptamines and their therapeutic uses
JP2025501630A (ja) * 2021-12-24 2025-01-22 サイロ プロプライエタリ リミテッド 化合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3939177A (en) * 1972-11-22 1976-02-17 Sterling Drug Inc. 4-Aminomethyl-9-benzyl-1,2,3,4-tetrahydrocarbazoles
GB8416724D0 (en) * 1984-06-30 1984-08-01 Sorbio Sa Lab Active compounds

Also Published As

Publication number Publication date
DE69930308D1 (de) 2006-05-04
CA2353962A1 (fr) 2000-06-15
MXPA01005905A (es) 2002-09-18
CA2353962C (fr) 2009-09-29
AU767009B2 (en) 2003-10-30
EP1149078A1 (fr) 2001-10-31
WO2000034242A1 (fr) 2000-06-15
EP1149078A4 (fr) 2003-01-29
DE69930308T2 (de) 2006-11-30
AU2356200A (en) 2000-06-26
EP1149078B1 (fr) 2006-03-08
ES2260958T3 (es) 2006-11-01
PT1149078E (pt) 2006-07-31
ATE319683T1 (de) 2006-03-15

Similar Documents

Publication Publication Date Title
DK1149078T3 (da) Selektive 5-HT6-receptorligander
DK1588706T3 (da) Valsartantablet
CO5011096A1 (es) Medicamentos que contienen antagonistas del receptor 5-ht3 para el tratamiento de la ibs
DK1196397T3 (da) Metabotrope glutamatreceptorantagonister og anvendelse deraf til behandling af sygdomme i centralnervesystemet
NO20015413D0 (no) Anvendelse av dopamin-D3-reseptor-ligander for fremstilling av medikamenter for behandling av nyrefunksjonsforstyrrelser
EP1194421A4 (fr) Antagonistes selectifs du npy (y5)
TR200102021T2 (tr) TWEAK ve TWEAK reseptörü antagonistleri ve bunların imünolojik bozuklukların iyileştirilmesi için kullanımları
EA200200560A1 (ru) Полициклоалкилпурины в качестве антагонистов аденозиновых рецепторов
DE60203797D1 (de) Benzo[d]azepin-derivative als 5-ht6-rezeptor-antagonisten
EA199900912A1 (ru) Фармацевтические средства
EE9900595A (et) Spetsiifilise 5-HT 2A-retseptori antagonisti kasutamine une hingamishäirete raviks kasulike ravimite valmistamiseks
HUP0203338A2 (hu) Integrin receptor ligandumok
TR200100240T2 (tr) Anksiyete bozukluklarının tedavisi
PT883401E (pt) Antagonista do receptor at1 para estimulacao da apoptose
WO2002017922A8 (fr) Composes de nicotine pontee utilises pour le traitement des troubles du systeme nerveux central
PT1143942E (pt) Uso de ligandos de receptores gaba para a manufactura de medicamentos para o tratamento de doencas neurodegenerativas
NO981188D0 (no) 5-HT3-reseptorantagonister for dyskinesi
DE69901716D1 (de) Pharmazeutische zusammensetzung enthaltend factor xiiia für nervenheilung